Yutiq Patent Expiration

Yutiq is a drug owned by Alimera Sciences Inc. It is protected by 10 US drug patents filed from 2018 to 2022. Out of these, 2 drug patents are active and 8 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 12, 2028. Details of Yutiq's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7998108 Injector apparatus and method of use
Jan, 2028

(3 years from now)

Active
US8871241 Injectable sustained release delivery devices
Aug, 2027

(2 years from now)

Active
US8574659 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Apr, 2020

(4 years ago)

Expired
US9192579 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Apr, 2020

(4 years ago)

Expired
US9849085 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Apr, 2020

(4 years ago)

Expired
US6375972 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Apr, 2020

(4 years ago)

Expired
US8574613 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Apr, 2020

(4 years ago)

Expired
US8252307 Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Jun, 2019

(5 years ago)

Expired
US6548078 Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Mar, 2019

(5 years ago)

Expired
US6217895 Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Mar, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Yutiq's patents.

Given below is the list of recent legal activities going on the following patents of Yutiq.

Activity Date Patent Number
Patent litigations
Expire Patent 01 Jan, 2024 US9192579
Maintenance Fee Reminder Mailed 17 Jul, 2023 US9192579
Payment of Maintenance Fee, 12th Year, Large Entity 01 Feb, 2023 US7998108
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 07 Apr, 2022 US7998108
Expire Patent 31 Jan, 2022 US9849085
Expire Patent 13 Dec, 2021 US8574613
Expire Patent 13 Dec, 2021 US8574659
Maintenance Fee Reminder Mailed 16 Aug, 2021 US9849085
Maintenance Fee Reminder Mailed 28 Jun, 2021 US8574613
Maintenance Fee Reminder Mailed 28 Jun, 2021 US8574659


FDA has granted several exclusivities to Yutiq. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Yutiq, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Yutiq.

Exclusivity Information

Yutiq holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Yutiq's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 12, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Yutiq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Yutiq's family patents as well as insights into ongoing legal events on those patents.

Yutiq's Family Patents

Yutiq has patent protection in a total of 27 countries. It's US patent count contributes only to 26.0% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Yutiq.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Yutiq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 12, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Yutiq Generic API suppliers:

Fluocinolone Acetonide is the generic name for the brand Yutiq. 27 different companies have already filed for the generic of Yutiq, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Yutiq's generic

Alternative Brands for Yutiq

Yutiq which is used for treating chronic non-infectious uveitis affecting the posterior segment of the eye., has several other brand drugs in the same treatment category and using the same active ingredient (Fluocinolone Acetonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch And Lomb
Retisert

(uses Fluocinolone Acetonide)

Used for managing chronic non-infectious uveitis affecting the posterior segment of the eye.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Fluocinolone Acetonide. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Alimera Sciences Inc
Iluvien
Galderma Labs Lp
Tri-luma
Laboratorios Salvat
Otovel


Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluocinolone Acetonide, Yutiq's active ingredient. Check the complete list of approved generic manufacturers for Yutiq





About Yutiq

Yutiq is a drug owned by Alimera Sciences Inc. It is used for treating chronic non-infectious uveitis affecting the posterior segment of the eye. Yutiq uses Fluocinolone Acetonide as an active ingredient. Yutiq was launched by Alimera Sciences Inc in 2018.

Approval Date:

Yutiq was approved by FDA for market use on 12 October, 2018.

Active Ingredient:

Yutiq uses Fluocinolone Acetonide as the active ingredient. Check out other Drugs and Companies using Fluocinolone Acetonide ingredient

Treatment:

Yutiq is used for treating chronic non-infectious uveitis affecting the posterior segment of the eye.

Dosage:

Yutiq is available in implant form for intravitreal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.18MG IMPLANT Prescription INTRAVITREAL